{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T05:31:18Z","timestamp":1766467878083,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.biopha.2009.06.020","type":"journal-article","created":{"date-parts":[[2009,10,28]],"date-time":"2009-10-28T04:26:11Z","timestamp":1256703971000},"page":"282-286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease"],"prefix":"10.1016","volume":"64","author":[{"given":"Eniko","family":"Vamos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krisztina","family":"Voros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laszlo","family":"Vecsei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Klivenyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2009.06.020_bib1","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1523\/JNEUROSCI.17-09-03052.1997","article-title":"Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum","volume":"17","author":"Ferrante","year":"1997","journal-title":"J Neurosci."},{"key":"10.1016\/j.biopha.2009.06.020_bib2","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.biopha.2009.06.020_bib3","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1523\/JNEUROSCI.19-07-02522.1999","article-title":"Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology","volume":"19","author":"Gutekunst","year":"1999","journal-title":"J Neurosci."},{"key":"10.1016\/j.biopha.2009.06.020_bib4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/hmg\/8.3.397","article-title":"Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin","volume":"8","author":"Schilling","year":"1999","journal-title":"Hum Mol Genet."},{"key":"10.1016\/j.biopha.2009.06.020_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bbr.2006.01.003","article-title":"Behaviour changes in a transgenic model of Huntington's disease","volume":"169","author":"Klivenyi","year":"2006","journal-title":"Behav Brain Res."},{"key":"10.1016\/j.biopha.2009.06.020_bib6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/exnr.1999.7135","article-title":"NMDA and non-NMDA receptor-mediated excitotoxicity are potentiated in cultured striatal neurons by prior chronic depolarization","volume":"159","author":"Chen","year":"1999","journal-title":"Exp Neurol."},{"issue":"Pt 6","key":"10.1016\/j.biopha.2009.06.020_bib7","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/brain\/119.6.2085","article-title":"Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease","volume":"119","author":"Antonini","year":"1996","journal-title":"Brain"},{"key":"10.1016\/j.biopha.2009.06.020_bib8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0896-6273(92)90165-A","article-title":"Cellular localization of a metabotropic glutamate receptor in rat brain","volume":"9","author":"Martin","year":"1992","journal-title":"Neuron"},{"key":"10.1016\/j.biopha.2009.06.020_bib9","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1074\/mcp.M500090-MCP200","article-title":"Proteomic analysis of protein expression and oxidative modification in r6\/2 transgenic mice: a model of Huntington disease","volume":"4","author":"Perluigi","year":"2005","journal-title":"Mol Cell Proteomics."},{"key":"10.1016\/j.biopha.2009.06.020_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/1531-8249(199901)45:1<25::AID-ART6>3.0.CO;2-E","article-title":"Biochemical abnormalities and excitotoxicity in Huntington's disease brain","volume":"45","author":"Tabrizi","year":"1999","journal-title":"Ann Neurol."},{"key":"10.1016\/j.biopha.2009.06.020_bib11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3940(01)02326-6","article-title":"Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model","volume":"315","author":"Schilling","year":"2001","journal-title":"Neurosci Lett."},{"key":"10.1016\/j.biopha.2009.06.020_bib12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev.pa.27.040187.001353","article-title":"The pharmacology of carnitine","volume":"27","author":"Bahl","year":"1987","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"10.1016\/j.biopha.2009.06.020_bib13","first-page":"387","article-title":"Protective effect of carnitine on lipoperoxide formation in rat brain","volume":"43","author":"Koudelova","year":"1994","journal-title":"Physiol Res."},{"key":"10.1016\/j.biopha.2009.06.020_bib14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.neuint.2004.07.008","article-title":"Proteomic analysis of specific brain proteins in aged SAMP8 mice treated with alpha-lipoic acid: implications for aging and age-related neurodegenerative disorders","volume":"46","author":"Poon","year":"2005","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.biopha.2009.06.020_bib15","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0531-5565(01)00116-4","article-title":"Carnitine as a free radical scavenger in aging","volume":"36","author":"Rockia Rani","year":"2001","journal-title":"Exp Gerontol."},{"key":"10.1016\/j.biopha.2009.06.020_bib16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0165-6147(93)90093-Y","article-title":"Sites of action of carnitine and its derivatives on the cardiovascular system: interactions with membranes","volume":"14","author":"Fritz","year":"1993","journal-title":"Trends Pharmacol Sci."},{"key":"10.1016\/j.biopha.2009.06.020_bib17","first-page":"263","article-title":"L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia","volume":"5","author":"Goety","year":"1990","journal-title":"Mov Disord."},{"key":"10.1016\/j.biopha.2009.06.020_bib18","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1523\/JNEUROSCI.22-20-08942.2002","article-title":"Therapeutic effects of cystamine in a murine model of Huntington's disease","volume":"22","author":"Dedeoglu","year":"2002","journal-title":"J Neurosci."},{"key":"10.1016\/j.biopha.2009.06.020_bib19","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002","article-title":"Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease","volume":"22","author":"Ferrante","year":"2002","journal-title":"J Neurosci."},{"key":"10.1016\/j.biopha.2009.06.020_bib20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1471-4159.2003.t01-1-01868.x","article-title":"Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease","volume":"86","author":"Klivenyi","year":"2003","journal-title":"J Neurochem."},{"key":"10.1016\/j.biopha.2009.06.020_bib21","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00702-004-0201-4","article-title":"Huntington's disease: pathomechanism and therapeutic perspectives","volume":"111","author":"Gardian","year":"2004","journal-title":"J Neural Transm."},{"key":"10.1016\/j.biopha.2009.06.020_bib22","doi-asserted-by":"crossref","first-page":"9345","DOI":"10.1073\/pnas.0508875103","article-title":"Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease","volume":"103","author":"McBride","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopha.2009.06.020_bib23","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/ana.410370213","article-title":"Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals","volume":"37","author":"Landwehrmeyer","year":"1995","journal-title":"Ann Neurol."},{"key":"10.1016\/j.biopha.2009.06.020_bib24","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/0896-6273(95)90345-3","article-title":"Widespread expression of Huntington's disease gene (IT15) protein product","volume":"14","author":"Sharp","year":"1995","journal-title":"Neuron"},{"key":"10.1016\/j.biopha.2009.06.020_bib25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/ng1193-259","article-title":"Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues","volume":"5","author":"Strong","year":"1993","journal-title":"Nat Genet."},{"key":"10.1016\/j.biopha.2009.06.020_bib26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0166-2236(00)01609-X","article-title":"Transcriptional dysregulation in Huntington's disease","volume":"23","author":"Cha","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.biopha.2009.06.020_bib27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0168-9525(03)00074-X","article-title":"Transcriptional abnormalities in Huntington disease","volume":"19","author":"Sugars","year":"2003","journal-title":"Trends Genet."},{"key":"10.1016\/j.biopha.2009.06.020_bib28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrn1386","article-title":"Experimental therapeutics in transgenic mouse models of Huntington's disease","volume":"5","author":"Beal","year":"2004","journal-title":"Nat Rev Neurosci."},{"key":"10.1016\/j.biopha.2009.06.020_bib29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2165\/00002512-200118090-00004","article-title":"Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment","volume":"18","author":"Halliwell","year":"2001","journal-title":"Drugs Aging"},{"key":"10.1016\/j.biopha.2009.06.020_bib30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/ana.410380304","article-title":"Aging, energy, and oxidative stress in neurodegenerative diseases","volume":"38","author":"Beal","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.biopha.2009.06.020_bib31","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/hmg\/11.9.1137","article-title":"Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin","volume":"11","author":"Wyttenbach","year":"2002","journal-title":"Hum. Mol. Genet."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332209001887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332209001887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:46:23Z","timestamp":1760093183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332209001887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0753332209001887"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2009.06.020","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2010,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2009.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}